| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Standard BioTools Inc.$0.85
-0.01 (-1.15%)
D 21Pipeline Score Diagnostics · Commercial
Market Cap
402.08 M
EPS
-0.25
P/E Ratio
-
Value Trade
4.16 M
SEC Financials
Q1 2026Dilution Risk
Revenue
21.15 M
R&D Expenses
2.12 M
Operating CF
-46.60 M
Total Assets
639.11 M
Total Liabilities
77.99 M
Equity
561.12 M
4.41 %
Week
9.24 %
1 Month
-10.43 %
3 Month
-20.16 %
6 Month
-82.3 %
5 Year
-92.37 %
All Time
Cash Data
Cash Position
455.18 M
Monthly Burn
15.53 M
Runway
26.6 mo
Burn Trend
SEC Filing
May 6, 2026
Overview
Volume
276.73 K
52 Week Range
0.87 - 1.72
% held by Insiders
4.29 %
% held by Institutions
76.1 %
Enterprise Value
-23.61 M
Total Shares
390.09 M
Short %
0.59 %
Float Shares
222.74 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
D21
Pipeline Score $42M
Pipeline ValueValuation Signal
1
Drugs Scored0.1x
rNPV / MCap Top 20%
Micro Cap (rank 739 of 923)
Percentile RankStandard BioTools Inc. faces pipeline headwinds (21/100), with $106M risk-adjusted pipeline value, led by Spanish Black Radish product in Healthy (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Spanish Black Radish product Unknown | Healthy | Phase 1 | NCT02137590 | 8% | $106M | COMPLETED | 20 | - | - | Nov 1, 2011 | - | May 14, 2014 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LAB
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
LAB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
LABStandard BioTools Announces Sale of Mass Cytometry Business and Illumina’s Buyout of Contingent Payments to Advance Merger with Treeline Biosciences
Standard BioTools announced the sale of its Mass Cytometry business to Multiplex Bio, ensuring continuity of product lines and customer relationships. The company also received a $30 million buyout related to Illumina's acquisition of its SomaLogic business. Additionally, the U.S. FTC has terminated the waiting period for the merger with Treeline Biosciences, with both transactions expected to close by the end of 2026.
Read more →LAB▼ -7.4%on this news
Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026
Standard BioTools Inc. has announced the publication date for its second quarter 2026 financial results, which will be released on August 5, 2026, after the U.S. market closes. The company aims to lead in the life science tools sector through innovation and operational excellence. Their products are designed to assist researchers in developing therapeutics more efficiently.
Read more →LAB▼ -5%on this newsshared move
Standard BioTools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction
Standard BioTools has filed a registration statement for its merger with Treeline Biosciences, expected to close in the second half of 2026. The combined entity will have over $900 million in cash and a robust clinical pipeline, including promising data for TLN-121 in lymphoma. Industry veteran Sue Desmond-Hellmann has joined Treeline's Board of Directors.
Read more →LAB▼ -30.2%on this news
Standard BioTools and Treeline Biosciences Announce Merger Agreement Combined company to operate as Treeline Biosciences, advancing a deep pipeline of small molecule inhibitors, protein degraders and targeted therapy ant
Standard BioTools Inc. and Treeline Biosciences, Inc. have announced a merger agreement in an all-stock transaction. The merger aims to consolidate resources and expertise, creating a combined company named Treeline Biosciences. With an expected cash balance of over $900 million at closing, the newly formed company will have a solid financial foundation to pursue its pipeline of small molecule inhibitors and other therapies. The transaction is anticipated to close in the second half of 2026, following necessary approvals.
Read more →LABStandard BioTools Reports First Quarter 2026 Financial Results
Standard BioTools Inc. reported its financial results for Q1 2026, showcasing a revenue of $21.1 million, reflecting a 5% increase from the previous year. The company achieved a 54% reduction in operating loss and a 78% improvement in adjusted EBITDA, indicating progress towards profitability. Despite challenges in instruments revenue, the overall financial health appears strong with substantial cash reserves to support future growth.
Read more →LABStandard BioTools to Announce First Quarter 2026 Financial Results on May 5, 2026
Standard BioTools Inc. has announced the release date for its first quarter 2026 financial results, which will be published on May 5, 2026, after the U.S. market closes. The company specializes in next-generation technologies that aid biomedical research, particularly in oncology and immunology. This announcement reflects the company's ongoing commitment to transparency and investor engagement.
Read more →LABStandard BioTools Reports Fourth Quarter and Full Year 2025 Financial Results
Standard BioTools Inc. reported strong financial results for Q4 and full year 2025, highlighting better-than-expected performance and operational efficiencies. The company anticipates revenue between $80 million and $85 million for fiscal year 2026. The strategic sale of SomaLogic to Illumina is expected to provide flexibility for future growth, although risks remain regarding integration and market conditions.
Read more →LABStandard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Standard BioTools Inc. has announced that it will release its fourth quarter and full year 2025 financial results on February 24, 2026, after the U.S. market closes. The company is known for its advanced technologies that assist biomedical researchers in developing better medicines. Their focus includes oncology, immunology, and immunotherapy, serving various research institutions globally.
Read more →LABStandard BioTools Completes Sale of SomaLogic to Illumina
Standard BioTools has completed the sale of SomaLogic to Illumina for $350 million upfront, with potential total proceeds of up to $425 million. The transaction is expected to enhance Standard BioTools' financial position, allowing for future growth and acquisitions. However, the company faces risks related to stockholder litigation and the realization of expected benefits.
Read more →LAB▲ +20.3%on this news
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2025 Revenue Preliminary, unaudited combined company revenue for the full year 2025 of approximately $185 million; Revenue from continuing operations o
Standard BioTools announced preliminary revenue results for the fourth quarter and full year 2025, reporting approximately $185 million in total revenue. The company exceeded its expectations and highlighted steady execution under its strategic goals. With plans to finalize the sale of SomaLogic to Illumina, Standard BioTools projects a significant cash position and aims for positive adjusted EBITDA in 2026. The results, however, are preliminary and will be adjusted following the completion of audits, with inherent risks related to integration and business performance acknowledged.
Read more →LABStandard BioTools Reports Third Quarter 2025 Financial Results
Standard BioTools Inc. reported its third quarter financial results for 2025, highlighting a strong performance and a focus on operational efficiency. The company is implementing a restructuring plan aimed at achieving over $40 million in annual cost savings by 2026. Despite workforce reductions, the outlook remains positive with expected revenue between $165 million and $175 million for the fiscal year.
Read more →LABStandard BioTools to Announce Third Quarter Financial Results on November 4, 2025
Standard BioTools Inc. announced it will publish its third quarter financial results on November 4, 2025, after the market closes. As a leading solutions provider, the company utilizes advanced technologies to aid biomedical researchers in accelerating the development of better medicines. Their proprietary methodologies are essential in various fields including oncology and immunotherapy, reflecting their commitment to improving patient outcomes.
Read more →LABStandard BioTools Reports Second Quarter 2025 Financial Results
Standard BioTools Inc. reported its financial results for the second quarter of 2025, registering total combined revenue of $42 million and revenue from continuing operations of $21.8 million. The company announced a strategic sale of SomaLogic to Illumina, potentially providing up to $425 million, which is anticipated to aid future growth. Operating expenses decreased by 11% year-over-year, showcasing improved financial management. Despite these positive aspects, the company experienced a 5% decline in revenue from continuing operations and ongoing market pressures.
Read more →LABStandard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health Study
Standard BioTools has partnered with Precision Health Research, Singapore, to utilize its SomaScan 11K Assay for the PRECISE-SG100K study, which will analyze 100,000 plasma samples. This collaboration aims to enhance precision medicine and healthcare outcomes in Singapore by leveraging extensive participant data. The initiative is expected to set a new standard for population-scale proteomics.
Read more →LABStandard BioTools Schedules Second Quarter Earnings Conference Call on August 11, 2025
Standard BioTools Inc. will announce its second quarter 2025 financial results on August 11, 2025. A conference call will be held at 4:30 p.m. ET to discuss these results and the company's operational progress. The call will be accessible via phone and online webcast, with an archive available afterward.
Read more →LAB▲ +17.1%on this news
Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina
Standard BioTools has announced the strategic sale of SomaLogic to Illumina for up to $425 million, including $350 million upfront. This move aims to simplify the company's operations and achieve adjusted EBITDA break-even. The deal retains certain commercialization rights for Standard BioTools, positioning it for future growth. The transaction is expected to close in the first half of 2026, pending regulatory approvals.
Read more →LABStandard BioTools to Host Inaugural “Proteomics Roundtable” Webcast Series
Standard BioTools Inc. has announced the launch of its inaugural Proteomics Roundtable Series, aimed at fostering discussions on advancements in proteomics. The first session will feature insights from researchers involved in a significant cancer study. Future sessions will cover various topics related to proteomic technologies and their applications in healthcare.
Read more →LAB▼ -7.8%on this news
Standard BioTools Reports First Quarter 2025 Financial Results
Standard BioTools Inc. reported its financial results for Q1 2025, highlighting revenue of $40.8 million and a 45% reduction in operating loss compared to the prior year. The company achieved a 29% improvement in adjusted EBITDA, driven by operational cost reductions totaling $90 million since the merger. Despite a 10% decline in revenue year-over-year, Standard BioTools emphasized its strong cash position of $261 million and advancements in proteomics technology, anticipating future growth. The firm expects a high single-digit annual decline in Americas academic revenue due to NIH funding pressures.
Read more →LABStandard BioTools Announces New Product Innovations in Plasma and Single-Cell Proteomics at AACR 2025
Standard BioTools Inc. has announced new product innovations in proteomics at the AACR Annual Meeting 2025. The launch includes the SomaScan Select 3.7K Assay and the CyTOF XT PRO system, aimed at enhancing translational and clinical research. The company emphasizes its commitment to advancing cancer research through innovative solutions and extensive participation in the conference.
Read more →LAB▲ +6.7%on this newsshared move
Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025
Standard BioTools Inc. has announced that it will report its first quarter 2025 financial results on May 6, 2025. Following the report, the company will host a conference call at 4:30 p.m. ET to discuss its financial performance and operational advancements. Investors can access the call via a dedicated phone line or through a live webcast on the company's Investor Relations page.
Read more →LAB▼ -10.7%on this news
Standard BioTools to Participate in Upcoming Investor Conferences
Standard BioTools Inc. will participate in several upcoming investor conferences, including TD Cowen's Annual Healthcare Conference and the Leerink Partners Global Healthcare Conference. Management is scheduled to present at specific times and will also engage in investor meetings. The presentations will be available for live viewing and archived on the company’s Investor Relations page, highlighting the firm's commitment to transparency and investor engagement.
Read more →LAB▼ -7.1%on this news· ran to -20% by day 3shared move
Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results
Standard BioTools announced its financial results for the fourth quarter and full year ended December 31, 2024, reporting full-year pro forma combined revenue of $175.1 million. The company achieved a 17% reduction in pro forma operating loss and a 33% improvement in adjusted EBITDA, alongside significant cost reductions totaling $90 million. However, the overall revenue dropped by 9% compared to the previous year, with notable declines in instruments revenue. The company has a strong balance sheet with $295 million in cash, positioning it well for future strategic initiatives.
Read more →LABStandard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025
Standard BioTools Inc. has announced the date for its fourth quarter and full year 2024 earnings conference call, scheduled for February 26, 2025. The call will take place after market close and will cover financial results along with operational progress. Investors can access the call through a dedicated telephone line or by attending a webcast on the company's Investor Relations page. The event aims to provide insights into the company's role in advancing biomedical research technologies.
Read more →LAB▲ +26.4%on this news
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2024 Revenue Preliminary, unaudited revenue for the full year 2024 of approximately $174 million Presenting at the 43 rd Annual J.P. Morgan Healthcare
Standard BioTools Inc. has announced preliminary revenue estimates for the fourth quarter and full year 2024, projecting approximately $174 million in revenue. CEO Michael Egholm noted significant efforts in reducing operating expenses while navigating industry challenges. The company anticipates improvements through integration of past acquisitions, signaling a strategic shift towards high-margin markets. However, the unaudited revenue results are subject to potential adjustments as the company completes its annual audit procedures.
Read more →LABStandard BioTools SomaScan Assay Powers Key Insights into Semaglutide Treatment Published in Nature Medicine
Standard BioTools Inc. announced that its SomaScan platform was pivotal in a new study published in Nature Medicine, which explored semaglutide's impact on obesity and broader health benefits. The research, involving nearly 2,000 participants, revealed crucial proteomic changes, enhancing the understanding of semaglutide's biological mechanisms. The findings underscore the importance of proteomics in advancing precision medicine and highlight the potential for developing new therapeutic indications for semaglutide.
Read more →LABStandard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Standard BioTools Inc. has announced that its President and CEO, Dr. Michael Egholm, will present at the 43rd Annual J.P. Morgan Healthcare Conference from January 13th to 16th, 2024. The presentation is scheduled for January 16th at 9:45 a.m. PT. Investors can access a live audio webcast of the presentation on the company's Investor Relations page. Standard BioTools, known for its technologies in biomedical research, continues to focus on advancements in health and disease.
Read more →LABStandard BioTools Appoints Alex Kim as Chief Financial Officer
Standard BioTools Inc. announced the appointment of Alex Kim as Chief Financial Officer, effective November 11, 2024. Kim, a co-founder of the company, brings nearly 30 years of experience in finance and operations within healthcare and life sciences. He has held significant roles in various companies and is expected to play a key role in the strategic and financial planning of Standard BioTools. This appointment reflects the company's ongoing commitment to achieving its financial targets and enhancing operational excellence.
Read more →LAB▲ +7.4%on this news· ran to +20% by day 3shared move
Standard BioTools Reports Third Quarter 2024 Financial Results
Standard BioTools Inc. reported its third quarter 2024 financial results, indicating a revenue of $45 million, a 5% decrease from the previous year. Positive metrics included a 50% improvement in adjusted EBITDA and a 35% decrease in net loss, attributed to merger cost synergies. The company remains focused on achieving adjusted EBITDA break-even by 2026, despite challenges in instrument sales and a significant net loss. They reiterated their 2024 revenue guidance of $170 million to $175 million.
Read more →LABStandard BioTools Announces Conference Call and Webcast for Third Quarter 2024 Financial Results on October 30, 2024
Standard BioTools Inc. announced that it will report its financial results for the third quarter of 2024 on October 30, 2024. A conference call and webcast will be held on the same day to discuss these results and the company's operational progress. The financial results will be shared before the call, and interested participants can join via a dedicated phone line or online webcast. Standard BioTools, formerly Fluidigm Corporation, is recognized for its innovative technologies aiding biomedical research.
Read more →LAB▲ +5.3%on this news
Standard BioTools Achieves New Record of the Most Protein Measurements on the Most Sample Types with Expansion of the SomaScan 11K Platform
Standard BioTools Inc. announced a significant expansion of its SomaScan® 11K Platform to include measurements from diverse sample types such as cerebrospinal fluid, aqueous humor, and tissue homogenates. This enhancement allows researchers to conduct up to 11,000 simultaneous protein measurements, facilitating advanced insights in areas like neurodegenerative diseases and drug development. The platform maintains precision and consistency, crucial for clinical trials using scarce biomaterials. This update signifies a continuous improvement strategy aimed at enhancing research capabilities in translational and clinical studies.
Read more →LABStandard BioTools proteomics profiling reveals unique biomarkers and insights into nonalcoholic steatohepatitis (NASH)
Standard BioTools Inc. announced a study published in Nature Scientific Reports, highlighting the use of its high-plex SomaScan Assay to identify biomarkers linked to nonalcoholic steatohepatitis (NASH) and nonalcoholic fatty liver disease (NAFLD). The study revealed 69 blood analytes correlating with clinical measures of liver inflammation, aiding in the stratification and monitoring of patients. Results indicated that the SomaSignal tests effectively demonstrated disease regression during a clinical trial that focused on the ACC1 inhibitor drug clesacostat. This advancement offers a promising noninvasive diagnostic method for these challenging diseases.
Read more →LABStandard BioTools 1 Unleashing Tools to Accelerate Breakthroughs in Human Health INVESTOR PRESENTATION September 2024 Legal Information 2 Forward-looking statements This presentation contains forward-looking statements t
Standard BioTools has presented its investor insights for Q2 2024, highlighting financial performance and strategic initiatives. The report shows a gradual improvement in revenue from SomaScan Assay Kits, although challenges remain with the services business due to macroeconomic factors. The company is focused on executing synergies to enhance gross margins and is making strides towards better operational efficiency. Despite setbacks, the pipeline remains robust, with expectations of revenue growth in the coming quarters.
Read more →LABStandard BioTools to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
Standard BioTools Inc. will present at the Morgan Stanley 22nd Annual Global Healthcare Conference from September 4-6, 2024. CEO Michael Egholm will host a fireside chat on September 6 at 8:30 a.m. ET. The presentation will be available via a live webcast and later archived on the company's Investor Relations page. Standard BioTools Inc. focuses on providing next-generation technologies to accelerate biomedical research and improve patient outcomes.
Read more →LABStandard BioTools Announces Senior Leadership Changes Alex Kim, Chief Operating Officer and Standard BioTools Co-Founder, to Serve as interim Chief Financial Officer Following Departure of Jeffrey Black on
Standard BioTools has announced leadership changes following the resignation of Chief Financial Officer Jeffrey Black, effective August 31, 2024. Alex Kim, the company's Chief Operating Officer and co-founder, will assume the role of interim CFO starting September 1, 2024. Additionally, Sean Mackay will expand his responsibilities to include product management, marketing, and investor relations. The company is actively seeking a permanent CFO to continue its strategic growth initiatives.
Read more →LABStandard BioTools Reports Second Quarter 2024 Financial Results Delivered revenue of $37.2 million Accelerated merger synergies with $80 million expected to be operationalized in 2024 Revised FY2024 revenue guidance; on-
Standard BioTools Inc. reported its second-quarter financial results, showcasing a revenue increase to $37.2 million, up 34% year-over-year. The company accelerated merger synergies, forecasting operational cost reductions of $80 million by the end of 2024 and aiming for adjusted EBITDA break-even by 2026. Despite these positives, the company faced challenges such as service contract delays and a net loss of $46 million for the quarter, reflecting ongoing macroeconomic pressures that contributed to revenue declines in its services sector.
Read more →LABStandard BioTools Announces Conference Call and Webcast for Second Quarter 2024 Financial Results on July 31, 2024
Standard BioTools Inc. has announced the date for its second quarter 2024 financial results, scheduled for July 31, 2024. The management will conduct a conference call and webcast to discuss these results and operational progress at 1:30 p.m. PT. A press release detailing the financial outcomes will precede the call, ensuring stakeholders are informed about the company's performance.
Read more →LABStandard BioTools Purchases the Carterra LSA-XT System to Accelerate Data Delivery and Provide Greater Validation to SomaScan Customers
Standard BioTools Inc. has acquired the Carterra LSA-XT system to improve data delivery and validation for its SomaScan Platform. This high-throughput system will assist in measuring the kinetic properties of reagents and enhance biomarker characterization. The collaboration aims to provide researchers with expanded capabilities in exploring proteomic biomarkers. The LSA-XT's efficiency promises to increase accuracy and speed in their research efforts.
Read more →LABStandard BioTools Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Standard BioTools Inc. announced the grant of 207,832 restricted stock units (RSUs) as an inducement for a new employee, effective May 20, 2024. This grant is in line with Nasdaq Listing Rule 5635(c)(4) and aims to attract talent in the biotech field. The RSUs will vest over a period, contingent upon the employee's continued service, which underscores the company's focus on retaining skilled professionals to support its growth.
Read more →LAB▼ -5.5%on this news
Standard BioTools Reports First Quarter 2024 Financial Results • Ahead of plan on operating expense synergies; $50 million of $80 million target to be achieved by year-end 2024 with remaining balance in FY2025 &#x
Standard BioTools reported its Q1 2024 financial results, showcasing advancements in operational efficiency and cost synergies, having achieved $50 million of its $80 million target ahead of schedule. The company's revenue reached $46.2 million, representing an 81% increase year-over-year, attributed in part to the integration of SomaLogic. Despite having solid revenue growth, the company faced challenges with a net loss of $50 million, prompting a focus on reducing expenses and enhancing cash flow sustainability. Standard BioTools remains optimistic about achieving cash flow positivity by 2026.
Read more →LABStandard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth Company expects to achieve $45-$50 million in annualized operating expense savings in fiscal 2025 Management to discuss firs
Standard BioTools has announced an operational restructuring plan aimed at enhancing efficiency and reducing operating costs, targeting annualized savings of $45-$50 million by fiscal 2025. This initiative follows a comprehensive business review post-merger with SomaLogic. While the plan reflects the company's commitment to profitability and growth, it will involve layoffs that may disrupt employee morale and customer relationships. A conference call is scheduled for May 8, 2024, to discuss the implications of this restructuring and the first quarter financial results.
Read more →LABStandard BioTools Announces Conference Call and Webcast for First Quarter 2024 Financial Results on May 8, 2024
Standard BioTools Inc. has scheduled a conference call and webcast for May 8, 2024, to discuss its first quarter financial results for 2024. The management will go over these results and offer insights into the company's operational progress after the market closes. Interested individuals can join the call through specified phone numbers, and a live audio webcast will also be available online.
Read more →LAB▲ +5.1%on this news
Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging
Standard BioTools Inc. has unveiled new high-throughput multiplexed whole slide imaging capabilities on its Hyperion XTi Imaging System. These innovations aim to enhance research with faster and more automated tissue imaging processes. The system features three operational modes to facilitate detailed and comprehensive analysis, significantly accelerating insights in spatial biology. The introduction of an automated slide loader further enhances productivity, allowing seamless loading of multiple slides and reducing manual handling errors.
Read more →LABStandard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan Platform for Translational Medicine Research
Standard BioTools Inc. has announced a multi-year strategic engagement with Bristol Myers Squibb to utilize the SomaScan Platform for clinical trials across various therapeutic areas until 2026. This platform enables comprehensive proteomic biomarker analysis, facilitating insights into patients' drug responses while reducing the need for invasive tests. Bristol Myers Squibb aims to enhance the identification of patient populations likely to benefit from their therapies, furthering their pipeline of transformative medicines. The collaboration is also focused on developing a blood test screening model for hypertrophic cardiomyopathy, enhancing early condition detection.
Read more →LABStandard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock
Standard BioTools Inc. has announced the exchange of all outstanding Series B Convertible Preferred Stock for common stock, in a move aimed at streamlining its capital structure. This agreement was reached with stockholders Viking Global Investors and Casdin Capital, which may enhance the company's attractiveness to new investors and potential M&A partners. CEO Michael Egholm highlighted the company's strategy for profitable growth and operational excellence as critical components of their future plans. The transaction resulted in the issuance of approximately 93 million shares of common stock, which represents a minor dilution of less than 5%. The elimination of significant liquidation preferences further aligns the interests of common stockholders.
Read more →LABStandard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results • Achieved FY2023 core financial objectives, delivering substantial ongoing reductions in expenses and cash burn while expanding revenu
Standard BioTools reported its financial results for Q4 and FY2023, highlighting significant achievements such as revenue growth and expense reductions despite challenging conditions in the life sciences sector. Notably, the merger with SomaLogic was completed, contributing to a combined pro forma revenue of $192 million and a strong cash position of $565 million at year-end. The company emphasized its strategic focus on operational efficiency and the integration of cutting-edge technologies. Looking ahead, Standard BioTools projects revenue growth for FY2024.
Read more →LABStandard BioTools and Next Gen Diagnostics Announce Partnership to Provide Complete Automation of Low-Cost Pathogen Sequencing
Standard BioTools Inc. has partnered with Next Gen Diagnostics to automate and enhance pathogen whole genome sequencing preparations. The agreement will utilize Standard BioTools' microfluidic systems, making bacterial sequencing more efficient and cost-effective. This collaboration is expected to address the previous bottlenecks in sequencing through integrated services while expanding the reach of both companies within the realm of infection control and clinical applications. The partnership is seen as a significant advancement in the market for pathogen genomics.
Read more →LABStandard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
Standard BioTools Inc. has announced it will report its fourth quarter and full year 2023 financial results on February 28, 2024. Following the release, management will host a conference call and webcast to discuss the financial outcomes and operational progress. This event underscores the company's commitment to transparency and communication with investors.
Read more →LABStandard BioTools and Navignostics Announce Collaboration Agreement to Advance Imaging Capabilities in Personalized Medicine
Standard BioTools Inc. has entered into a collaboration agreement with Navignostics AG to enhance imaging capabilities in personalized medicine. This partnership will leverage the Hyperion XTi Imaging System for clinical research applications, focusing on precision cancer treatments through Imaging Mass Cytometry. Both companies aim to advance cancer diagnostics and improve treatment outcomes by working on innovative methodologies and co-publishing research findings. This effort signifies a strong commitment to integrating advanced technologies in clinical settings for better healthcare solutions.
Read more →LAB▲ +13.4%on this news
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2023 Revenue Achieving scale with pro forma full year 2023 revenue of approximately $192 million
Standard BioTools, following its recent merger with SomaLogic, announced preliminary revenue results for Q4 and full year 2023, with expected revenues approximating $192 million. This represents a growth of over 10% in core revenue, attributed to a significant increase in instrument sales. The company also reported strong cash reserves exceeding $550 million. However, the announced figures are subject to change pending further audits and there are inherent risks associated with the merger's operational integration.
Read more →LABStandard BioTools Completes Merger with SomaLogic, Creating a Diversified and Scaled Leader in Life Sciences Tools
Standard BioTools has officially completed its merger with SomaLogic, creating a prominent entity in life sciences tools focused on multi-omic technologies. Shareholders of SomaLogic will receive stock from Standard BioTools as their stock ceases trading. The merger is aimed at leveraging combined strengths to enhance profitability, boost operational performance, and achieve significant cost synergies while maintaining a robust financial outlook. Leadership appointments have also been made to ensure effective management and direction of the newly formed company.
Read more →LAB▼ -5.4%on this newsshared move
Standard BioTools Stockholders Approve Merger with SomaLogic
Standard BioTools has announced that its stockholders approved all necessary proposals for the merger with SomaLogic. The approval reflects strong support for the merger, which aims to create an expanded platform to better serve customers. The merger is expected to close on January 5, 2024, subject to customary conditions. Both companies anticipate the merger will lead to significant shareholder value through enhanced scale and a stronger financial position.
Read more →LABGlass Lewis Recommends Standard BioTools Stockholders Vote "FOR" All Proposals Relating to Proposed Merger with SomaLogic SOUTH SAN FRANCISCO, Calif.
Glass Lewis has advised Standard BioTools stockholders to vote in favor of all proposals regarding the merger with SomaLogic, reinforcing the confidence in this pending merger. This recommendation follows a similar endorsement from ISS, bolstering the company's position as they approach the upcoming Special Meeting of Stockholders on January 4, 2024. The merger is on track to finalize in the first quarter of 2024, subject to stockholder approvals and customary closing conditions.
Read more →LABISS Recommends Standard BioTools Stockholders Vote "FOR" All Proposals Relating to Proposed Merger with SomaLogic SOUTH SAN FRANCISCO, Calif.
Standard BioTools Inc. (Nasdaq: LAB) has received a favorable recommendation from ISS for its stockholders to vote in support of all proposals associated with the proposed merger with SomaLogic. This recommendation highlights the anticipated benefits of the merger, including a significantly accelerated path to profitability for Standard BioTools. The merger's completion is projected for the first quarter of 2024, contingent on approval from both companies' stockholders and other customary conditions being satisfied. A special meeting of stockholders is scheduled for January 4, 2024, to discuss the merger proposals.
Read more →LAB▲ +7.7%on this newsshared move
Investor Presentation Unlocking Value in a Fragmented Space DECEMBER 2023 Legal Information 3 (1) Assumes transaction close in Q1 2024. Total cost synergies exclude non - cash, restructuring - related and other non - rec
Standard BioTools (LAB) is set to merge with SomaLogic (SLGC) in Q1 2024, aiming to create a combined entity projected to generate over $300 million in revenue by 2026. The merger anticipates $80 million in cost synergies and positions the companies to better capitalize on current market dynamics favoring larger, diversified firms. Despite SLGC experiencing significant share value decline since its public debut, the merger is structured to retain majority control for shareholders, with synergies anticipated to enhance profitability and scale. The transaction is still subject to shareholder approval, with a critical vote scheduled for January 4, 2024.
Read more →LABStandard BioTools and SomaLogic Announce Date for Special Meetings of Stockholders to Vote on Proposed Merger SOUTH SAN FRANCISCO, Calif. and
Standard BioTools Inc. and SomaLogic, Inc. have scheduled special meetings of stockholders to vote on their proposed all-stock merger. The meetings will take place virtually on January 4, 2024, for stockholders who were on record as of November 29, 2023. The merger is anticipated to close in the first quarter of 2024, subject to stockholder approval and other customary conditions. The companies have filed necessary proxy materials with the SEC for review by their stockholders.
Read more →LABStandard BioTools Activating Strategy to Become a Diversified Leader in Life Sciences Tools NOVEMBER 2023 Legal Information 2 Forward-looking statements This presentation contains forward-looking statements that are subj
Standard BioTools is implementing a strategy to evolve into a diversified leader in life sciences tools. The company aims to establish a robust portfolio of multi-omic technologies and expects to achieve over $300 million in combined revenue and $80 million in run-rate synergies by 2026. Strong leadership and operational expertise will facilitate potential growth and cross-selling opportunities in lucrative markets. The performance indicators reflect progress, including a 10% increase in year-over-year revenue for the first three quarters of 2023, signaling positive momentum for the company.
Read more →LABStandard BioTools Reports Third Quarter and Year-to-Date 2023 Financial Results • Year-to-date revenue growth, gross margin expansion and operating expense reduction are testament to continued execution against fi
Standard BioTools reported its third quarter 2023 financial results, showcasing strong year-to-date revenue growth and enhanced gross margins. The company indicated a significant reduction in operating expenses and announced a planned all-stock merger with SomaLogic, which is expected to build a diversified leader in life science tools. Despite these positive developments, Standard BioTools acknowledged some headwinds, including a reported operating loss and revenue declines in the third quarter. The company is maintaining a disciplined approach to investments and raised its financial outlook for 2023, highlighting a focus on long-term transformation.
Read more →LABStandard BioTools to Present at the Jefferies London Healthcare Conference
Standard BioTools Inc. (Nasdaq:LAB) has announced that its CEO, Michael Egholm, will present at the Jefferies London Healthcare Conference on November 15, 2023. The presentation will include a moderated Q&A session, further promoting transparency and stakeholder engagement. This event is part of the company's ongoing efforts to highlight its role in advancing biomedical research and improving patient outcomes through innovative technologies.
Read more →LAB▼ -10.5%on this news
Standard BioTools Announces Conference Call and Webcast of Third Quarter 2023 Financial Results on November 7, 2023
Standard BioTools Inc. (Nasdaq:LAB) has announced it will release its third quarter 2023 financial results on November 7, 2023, after market closure. A management conference call and webcast will follow at 1:30 p.m. PT to discuss these results and operational updates. The press release containing detailed financial data will be available before the call. Investors can access the live webcast on the company's Investor Relations webpage, which will also host an archived version later.
Read more →LAB▼ -22.2%on this news· ran to -33% by day 3
Standard BioTools and SomaLogic to Combine in All-Stock Merger Creating a Diversified Leader in Life Sciences Tools Activates Standard BioTools' strategy to unlock value in underserved portion of $100 billion industry Es
Standard BioTools and SomaLogic have announced an all-stock merger aimed at creating a leading provider of multi-omics tools for research. The combined company will have a pro-forma equity value exceeding $1 billion and project significant cost synergies of $80 million by 2026. Both companies have increased their revenue guidance for 2023, with total estimated combined revenue of $180 million. The transaction is expected to close in the first quarter of 2024, pending shareholder and regulatory approvals.
Read more →LABStandard BioTools Reports Second Quarter 2023 Financial Results
Standard BioTools Inc. has reported its financial results for the second quarter of 2023, highlighting a 47% increase in total revenue compared to the same quarter in 2022. The company also noted a significant improvement in non-GAAP gross margin and a reduction in operating expenses. However, despite these gains, Standard BioTools continues to operate at a loss, and its cash reserves have decreased from the previous year. The launch of new products, such as the Hyperion XTi Imaging System, is a focal point for the company’s growth strategy.
Read more →LABStandard BioTools Announces Conference Call and Webcast for Second Quarter 2023 Financial Results
Standard BioTools Inc. has announced that it will release its financial results for the second quarter of 2023 on August 8, 2023, after market close. Management will host a conference call and webcast at 2:00 p.m. PT to discuss the financial results and operational developments. The press release containing the financial results will be publicly available before the call, and the audio will also be archived on the company's Investor Relations page.
Read more →LABStandard BioTools to Present at the Jefferies Healthcare Conference
Standard BioTools Inc. announced that its CEO, Michael Egholm, will present at the Jefferies Healthcare Conference on June 8, 2023. The presentation will focus on the company's innovations and contributions to human health. As a recognized provider of next-generation technologies, Standard BioTools aims to enhance the efficiency of biomedical research. The event is part of their ongoing efforts to showcase their proprietary technologies in areas such as oncology and immunology.
Read more →LAB▲ +12.1%on this news· ran to +27% by day 3
Standard BioTools Announces NGS Library Preparation as an Upgrade on the X9 High-Throughput Genomics System
Standard BioTools Inc. has announced the introduction of next-generation sequencing (NGS) library preparation functionality on its X9 High-Throughput Genomics System. This upgrade allows users to conduct real-time PCR and NGS library preparation on a single compact benchtop system, enhancing efficiency and minimizing reagent use. The system can produce up to 384 sequencing-ready libraries daily, promising improved workflow and reduced errors during sample preparation. However, the company highlights several uncertainties related to its future financial performance and potential risks stemming from restructuring efforts.
Read more →LAB▲ +7.3%on this news· ran to +23% by day 3shared move
Standard BioTools Appoints Jeffrey Black as Chief Financial Officer and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Industry veteran Jeffrey Black brings 30 years of financial and operating leadershi
Standard BioTools Inc. has appointed Jeffrey Black as Chief Financial Officer, effective immediately. Bringing 30 years of financial and operational leadership experience, Black will oversee finance, accounting, and investor relations, reporting to CEO Michael Egholm. Vikram Jog will continue as a Special Advisor during the transition. Black's prior experience includes roles at Apollo Endosurgery and Alphatec Holdings, positioning him to contribute significantly to the company's growth initiatives.
Read more →LABStandard BioTools Reports First Quarter 2023 Financial Results Net cash used in operating activities of $8.5 million, a 55.8% sequential decline from $19.2 million in the fourth quarter and a 46% reduction from the $15.6
Standard BioTools Inc. reported its financial results for Q1 2023, highlighting a significant reduction in cash burn to $8.5 million, marking a 55.8% decline from the previous quarter. The company noted a 1.8% year-over-year increase in core product and service revenue, although GAAP revenue decreased by 5.2%. Improvement was seen in product and service margins, and the launch of the Hyperion XTi Imaging System positions the company favorably in the spatial biology market. Overall, while there were positive operational metrics, there were also concerns regarding revenue performance and ongoing expenses.
Read more →LABStandard BioTools Announces Conference Call and Webcast for First Quarter 2023 Financial Results
Standard BioTools Inc. will report its first-quarter 2023 financial results on May 9, 2023, following the market's close. A conference call and webcast are scheduled for the same day at 2:00 p.m. PT to discuss these results and operational progress. A press release with the financial results will be made available prior to the call, and the webcast will be accessible online afterward.
Read more →LABStandard BioTools Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Standard BioTools Inc. (Nasdaq:LAB) announced equity awards under its 2022 Inducement Equity Incentive Plan to attract new employees. The grants include 43,700 restricted stock units and stock options totaling 400,000 shares, effective from April 20, 2023. The vesting schedule spans over the next few years, contingent on the continued service of the new employees. This move aims to bolster the company's workforce as it pursues advancements in biomedical research.
Read more →LABStandard BioTools introduces the Hyperion XTi Imaging System, breaks barriers to power significant advancement in spatial biology
Standard BioTools Inc. announced the launch of the Hyperion XTi Imaging System during the AACR meeting. This next-generation imaging system enhances spatial biology research by processing single-cell data five times faster than previous models, allowing researchers to image up to 40 slides daily. The technology overcomes limitations of traditional fluorescence-based systems by reliably detecting over 40 biomarkers without interference. Despite its advancements, the company acknowledges potential risks related to product performance, supply chain issues, and competition.
Read more →LABStandard BioTools Announces Appointment of Fenel Eloi to Board of Directors
Standard BioTools Inc. has appointed Fenel Eloi to its Board of Directors, as the company enters a new phase of transformation. Eloi, who has a robust background in the life science tools industry, aims to leverage his experience to help guide the company in its mission. Concurrently, Bill Colston will retire from the Board. This strategic appointment reflects Standard BioTools' ambitions to enhance its leadership and operational success.
Read more →LAB▲ +11.1%on this newsshared move
Standard BioTools to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
Standard BioTools Inc. has announced its participation in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum, scheduled for March 21, 2023. CEO Michael Egholm will engage in a fireside chat during this event. The presentation will be webcast live and accessible via the company's Investor Relations webpage. Standard BioTools, formerly known as Fluidigm Corporation, focuses on developing next-generation technologies for biomedical research.
Read more →LABStandard BioTools to Present at 43rd Annual Cowen Health Care Conference
Standard BioTools Inc. will present at the Cowen Health Care Conference on March 8, 2023. The presentation will be led by the company's President and CEO, Michael Egholm, and will be available via live webcast. Standard BioTools, formerly known as Fluidigm Corporation, focuses on developing technologies that enhance biomedical research and improve patient outcomes. The company collaborates with various entities in the research and clinical sectors globally.
Read more →LABStandard BioTools Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Business Outlook Fourth quarter 2022 GAAP revenues of $27.0 million; Core product and service revenues of $26.8 million, rep
Standard BioTools reported its financial results for the fourth quarter and full year 2022, showing an increase in fourth quarter revenues to $27 million, representing an 8.3% sequential growth. The company expects flat to moderate growth in core product revenues for 2023, influenced by a $5 million transitory headwind in the Genomics sector. Improved operating margins and reduced operational expenses are anticipated due to ongoing restructuring efforts, with a target for GAAP gross margins to expand significantly by the end of the year. The financial results illustrate both progress and challenges faced by the company as it positions itself for future growth.
Read more →LABStandard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2022 Financial Results
Standard BioTools Inc. has announced that it will report its fourth quarter and full year 2022 financial results on February 14, 2023, after market close. Following the report, the management will conduct a conference call and webcast to discuss the results and operational progress. Interested parties can access the call both via phone and online, ensuring wide reach and transparency for investors.
Read more →LAB▲ +6.5%on this news· ran to +22% by day 3
Standard BioTools Provides Preliminary Fourth Quarter 2022 Revenue and Business Update Continued commercial and strategic execution delivers sequential core revenue growth of 4% - 9% to $26 million - $27 million in Q4 20
Standard BioTools has announced preliminary financial results for the fourth quarter of 2022, expecting core revenue growth of 4%-9% to reach between $26 million and $27 million. The company has undertaken a restructuring plan expected to reduce operating expenses by over $30 million. Management also anticipates positive free cash flow by the end of 2024, despite facing some challenges related to legacy operations. The firm expects to report detailed financial results in mid-February, clarifying its strategic plans for 2023.
Read more →LAB▲ +11.1%on this news· ran to +32% by day 3
Standard BioTools Announces Appointment of Betsy Jensen as Chief Human Resources Officer
Standard BioTools Inc. has appointed Betsy Jensen as its new Chief Human Resources Officer. Jensen, who has a rich background in HR leadership, previously served at Gibraltar and various Danaher subsidiaries. Her role will involve leading the company's HR function and supporting its strategies for growth and profitability. The appointment is seen as crucial for strengthening the management team and enhancing the company's culture.
Read more →LAB▲ +10%on this news
Standard BioTools Authorizes up to $20 Million of Share Repurchases
Standard BioTools Authorizes up to $20 Million of Share Repurchases FRANCISCO, Calif., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose - unleashing tools to accelerate breakthroughs in human health - today announced that its boar
Read more →LABStandard BioTools Announces Third Quarter 2022 Financial Results
Third quarter core product and services revenue increase of 30% sequentially to $24.8 million First phase of restructuring program improves operating margin by 600 to 800 basis points, or $8.0 million net on an annualized basis Reiterate stated goal of 700 to 1000 basis point n
Read more →LAB▼ -9.8%on this newsshared move
Standard BioTools and Visiopharm Announce Partnership for the Development of Complete Image Analysis Solutions to be Packaged With Hyperion and Hyperion+ Imaging Systems
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – and Visiopharm® today announced a collaboration to pair the company’s Hyperion™ and Hyperi
Read more →LAB▲ +15%on this news
Standard BioTools Announces Conference Call and Webcast of Third Quarter 2022 Financial Results
SOUTH SAN FRANCISCO, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – today announced that it will report third quarter 2022 financial results on Tuesday, Novem
Read more →LABStandard BioTools Releases the X9 Real-Time PCR System, Its Most Productive and Flexible High-Capacity Genomics Platform
SOUTH SAN FRANCISCO, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced the launch of the X9™ Real-Time PCR System, an innovative high-capacity g
Read more →LAB▲ +7.9%on this news
Standard BioTools Announces Second Quarter 2022 Financial Results and Provides Strategic Update
Second quarter revenue of $18.8 million Completed $250 million strategic cash infusion from Casdin Capital and Viking Global Upgraded management team and added board members to bring significant sector and operational expertise to the company Commenced restructuring program wi
Read more →LAB▼ -6.8%on this news
Standard BioTools Announces Conference Call and Webcast of Second Quarter 2022 Financial Results
SOUTH SAN FRANCISCO, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – today announced that it will report second quarter 2022 financial results on Monday, Augus
Read more →LABStandard BioTools Announces First Quarter 2022 Financial Results
SOUTH SAN FRANCISCO, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – today announced financial results for the first quarter ended March 31, 2022. “The end of
Read more →LABStandard BioTools Announces Conference Call and Webcast of First Quarter 2022 Financial Results
SOUTH SAN FRANCISCO, Calif., April 22, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – today announced that it will report first quarter 2022 financial results on Thursday, May
Read more →LABStandard BioTools Launches Hyperion+ Imaging System, the New Standard in High-Plex Spatial Imaging
SOUTH SAN FRANCISCO, Calif., April 11, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – unleashing tools to accelerate breakthroughs in human health – today announced the launch of the Hyperion+™ Imaging System, the new standard in high-ple
Read more →LABFluidigm Stockholders Approve $250 Million Strategic Capital Infusion
Fluidigm Stockholders Approve $250 Million Strategic Capital Infusion SOUTH SAN FRANCISCO, Calif., April 01, 2022 (GLOBE NEWSWIRE) Fluidigm Corporation (Nasdaq:FLDM) today announced that its stockholders have voted to approve all of the proposals related to the previously annou
Read more →LABFluidigm Announces Support Agreement with Caligan Partners Related to $250 Million Strategic Capital Infusion by Casdin Capital and Viking Global Caligan Partners to Vote FOR Casdin and Viking Transaction and All Other F
Fluidigm Announces Support Agreement with Caligan Partners Related to $250 Million Strategic Capital Infusion by Casdin Capital and Viking Global Caligan Partners to Vote FOR Casdin and Viking Transaction and All Other Fluidigm Proposals at the Special Meeting to be Reconvened
Read more →LABFluidigm Adjourns Special Meeting of Stockholders Until
Fluidigm Adjourns Special Meeting of Stockholders Until April 1, 2022 Provides Stockholders Additional Time to Consider $250 Million Strategic Capital Infusion from Casdin Capital and Viking Global Investors SOUTH SAN FRANCISCO, Calif., Mar. 25, 2022 Fluidigm Corporation (NASD
Read more →LABFluidigm Announces $250 Million Strategic Capital Infusion from Casdin Capital and Viking Global Investors and Rebranding to Standard BioTools Inc. Mission to Reinvigorate Growth through Optimization of Mass Cytometry an
Fluidigm Announces $250 Million Strategic Capital Infusion from Casdin Capital and Viking Global Investors and Rebranding to Standard BioTools Inc. Mission to Reinvigorate Growth through Optimization of Mass Cytometry and Microfluidics Platforms and Portfolio Expansion via Stra
Read more →LABDr. Ana K. Stankovic, MD, PhD, Appointed to Fluidigm Board of Directors
Dr. Ana K. Stankovic, MD, PhD, Appointed to Fluidigm Board of Directors SOUTH SAN FRANCISCO, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) - Fluidigm Corporation (Nasdaq FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight
Read more →LABFluidigm Corporation Announces Proposed Private Offering of $45 Million of Convertible Senior Notes
Fluidigm Corporation Announces Proposed Private Offering of $45 Million of Convertible Senior Notes SOUTH SAN FRANCISCO, Calif., Nov. 20, 2019 (GLOBE NEWSWIRE) - Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life throu
Read more →LABFLUIDIGM ANNOUNCES Q4 AND FULL YEAR 2016
FLUIDIGM ANNOUNCES Q4 AND FULL YEAR 2016 FINANCIAL RESULTS SOUTH SAN FRANCISCO, Calif., February 8, 2017 - Fluidigm Corporation (NASDAQ:FLDM) today announced its financial results for the fourth quarter and full year ended December 31, 2016. Total revenue for the fourth quarte
Read more →LABFLUIDIGM ANNOUNCES PRELIMINARY REVENUE FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2016
FLUIDIGM ANNOUNCES PRELIMINARY REVENUE FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2016 SOUTH SAN FRANCISCO, Calif., January 9, 2017 Fluidigm Corporation (NASDAQ:FLDM) today announced preliminary revenue for the fourth quarter and full year ended December 31, 2016.
Read more →LABFLUIDIGM
FLUIDIGM ANNOUNCES THIRD QUARTER FINANCIAL RESULTS SOUTH SAN FRANCISCO, Calif., November 3, 2016 - Fluidigm Corporation (NASDAQ:FLDM) today announced its financial results for the third quarter ended September 30, 2016. Total revenue for the third quarter of 2016 was $22.2 mill
Read more →LABSEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release ( Agreement ) is made by and between Gajus V. Worthington ( Executive ) and Fluidigm Corporation (the Company ) (jointly referred to as the Parties o
SEPARATION AGREEMENT AND RELEASE This Separation Agreement and Release ( Agreement ) is made by and between Gajus V. Worthington ( Executive ) and Fluidigm Corporation (the Company ) (jointly referred to as the Parties or individually referred to as a Party ). Executive was em
Read more →LABFLUIDIGM ANNOUNCES PRELIMINARY THIRD QUARTER 2016
FLUIDIGM ANNOUNCES PRELIMINARY THIRD QUARTER 2016 REVENUE SOUTH SAN FRANCISCO, Calif., October 12, 2016 - Fluidigm Corporation (NASDAQ:FLDM) today announced preliminary revenue for the third quarter ended September 30, 2016. Estimated total revenue for the third quarter of 2016
Read more →LABFLUIDIGM APPOINTS NEW PRESIDENT AND CHIEF OPERATING OFFICER Seasoned Life Science industry veteran joins Fluidigm to lead sustainable growth
FLUIDIGM APPOINTS NEW PRESIDENT AND CHIEF OPERATING OFFICER Seasoned Life Science industry veteran joins Fluidigm to lead sustainable growth SOUTH SAN FRANCISCO, Calif., Aug 4, 2016 Fluidigm Corporation (NASDAQ: FLDM) today announced the appointment of Chris Linthwaite as Presi
Read more →Competitive Position
How LAB ranks across every disease it competes inCompetitive Position is a premium feature
See how LAB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial